中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

380 records (took 0.022 seconds)

    LEUKOCYTE-SPECIFIC CELL PENETRATING MOLECULES
    1.
    发明申请
    LEUKOCYTE-SPECIFIC CELL PENETRATING MOLECULES 审中-公开

    公开(公告)号：WO2023028486A1

    公开(公告)日：2023-03-02

    申请号：PCT/US2022/075348

    申请日：2022-08-23

    Applicant: AMYTRX THERAPEUTICS, INC.

    Inventor： ALVAREZ, Vernon ,  GONDA, Matthew, A.

    IPC: A61K38/10 ,  A61K38/04 ,  C07K4/00 ,  C07K7/04

    Abstract: Disclosed herein are leukocyte-targeting molecules, pharmaceutical compositions comprising leukocyte-targeting molecules and an optional pharmaceutical agent, and methods of using same. In some embodiments, a leukocyte-targeting molecule is a peptide having the formula: X1X2AAX3AX4X5X17AX6X7X8AX9X10A(P)nX11x12(X13)n, or a pharmaceutically acceptable salt thereof; wherein X1, X2, X11, and X12 are each, independently, lysine, arginine, or ornithine; X3, X4, X5, X6, X7, X8, X9, and X10 are each, independently, valine, leucine, isoleucine, or norleucine; X13 is tyrosine; X17 is praline or alanine; and n is 0 or 1.

    A PEPTIDE WITH ABILITY TO PENETRATE CELL MEMBRANE
    8.
    发明申请
    A PEPTIDE WITH ABILITY TO PENETRATE CELL MEMBRANE 审中-公开
    一种具有穿透细胞膜能力的肽

    公开(公告)号：WO2017176076A1

    公开(公告)日：2017-10-12

    申请号：PCT/KR2017/003790

    申请日：2017-04-06

    Applicant: EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION

    Inventor： LEE, Kyung Lim ,  BAE, Hea Duk ,  MAENG, Jee Hye

    IPC: C07K7/06 ,  A61K47/50 ,  A61K39/00 ,  C07K4/00 ,  C07K14/575 ,  C07K14/605 ,  A61K38/22 ,  A61K38/26

    Abstract: The present invention relates to a novel, translationally controlled tumor protein derived-protein transduction domain (TCTP-PTD) having the ability to penetrate the cell membrane, and to the use thereof. The TCTP-PTD　peptide of the present invention is capable of improving the ability of a target substance to penetrate the cell membrane to thereby effectively deliver the target substance into a living body, including cells, tissue and blood. Thus, the TCTP-PTD　peptide may be used for research purposes in vitro , and may be used for clinical purposes, including treatment of various diseases, delivery of contrast agents, etc., and may also be used for diagnostic purposes and in cosmetic applications.

    Abstract translation: 本发明涉及具有穿透细胞膜的能力的新型翻译控制的肿瘤蛋白衍生蛋白转导结构域（TCTP-PTD），并涉及其用途。 本发明的TCTP-PTD肽能够提高目标物质穿透细胞膜的能力，从而有效地将目标物质递送到包括细胞，组织和血液的活体中。 因此，TCTP-PTD肽可以用于体外研究目的，并且可以用于临床目的，包括治疗各种疾病，输送造影剂等，并且也可以用于 用于诊断目的和化妆品应用。

    METHOD OF USING IL-27 AS A PREDICTIVE BIOMARKER OF CLINICAL RESPONSE TO GLATIRAMER ACETATE THERAPY
    9.
    发明申请
    METHOD OF USING IL-27 AS A PREDICTIVE BIOMARKER OF CLINICAL RESPONSE TO GLATIRAMER ACETATE THERAPY 审中-公开
    使用IL-27作为临床反应的预测性生物标记物的方法用于GLATIRAMER ACETATE治疗

    公开(公告)号：WO2017100199A1

    公开(公告)日：2017-06-15

    申请号：PCT/US2016/065175

    申请日：2016-12-06

    Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD. ,  ITO, Kouichi ,  DHIB-JALBUT, Suhayl

    Inventor： ITO, Kouichi ,  DHIB-JALBUT, Suhayl

    IPC: A61K38/03 ,  C07K4/00 ,  G01N33/50

    CPC classification number: G01N33/6869 ,  A61K38/02 ,  G01N2333/54 ,  G01N2333/5428 ,  G01N2800/285

    Abstract: The present invention provides a method for treating a subject afflicted with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: a) administering a therapeutic amount of the pharmaceutical composition to the subject; b) determining whether the subject is a glatiramer acetate responder by evaluating IL-27 concentration in the blood of the subject; and c) continuing the administration of the pharmaceutical composition if the subject is identified as a glatiramer acetate responder, or modifying treatment of the subject if the subject is not identified as a glatiramer acetate responder.

    Abstract translation: 本发明提供了用包含醋酸格拉替雷和药学上可接受的载体的药物组合物治疗患有多发性硬化症的受试者的方法，其包括以下步骤：a）将治疗量的药物组合物 对象; b）通过评估受试者血液中的IL-27浓度来确定受试者是否是醋酸格拉替雷应答者; 和c）如果受试者被鉴定为醋酸格拉替雷应答者，则继续施用药物组合物，或者如果受试者未被鉴定为醋酸格拉替雷应答者，则改变受试者的治疗。

    COMPOSITIONS AND METHODS FOR MODULATUION OF IMMUNE RESPONSE
    10.
    发明申请
    COMPOSITIONS AND METHODS FOR MODULATUION OF IMMUNE RESPONSE 审中-公开
    用于免疫应答调控的组合物和方法

    公开(公告)号：WO2015123493A3

    公开(公告)日：2015-12-17

    申请号：PCT/US2015015761

    申请日：2015-02-13

    Applicant: UNIV NORTHWESTERN

    Inventor： STEHLIK CHRISTIAN

    IPC: A61K38/00 ,  A61K39/395 ,  C07K4/00 ,  C07K16/00

    CPC classification number: A61K38/1709

    Abstract: Provided herein are compositions and methods for modulation of immune response via PYRIN domain-only proteins POP1 and/or POP3. In particular, POP1 and/or POP3 are inhibited to enhance an immune response (e.g., to treat or prevent infection), or POP1 and/or POP3 are administered or activated to reduce an immune response (e.g., to treat or prevent autoimmune or inflammatory disease).

    Abstract translation: 本文提供了通过PYRIN仅结构域蛋白质POP1和/或POP3调节免疫应答的组合物和方法。 特别地，POP1和/或POP3被抑制以增强免疫应答（例如，治疗或预防感染），或者POP1和/或POP3被施用或激活以减少免疫应答（例如，治疗或预防自身免疫或炎症 疾病）。

Patent Agency Ranking